Latest News and Press Releases

DUBLIN, Ireland and TREVOSE, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

~ KEVEYIS® (dichlorphenamide) First Quarter 2018 Revenue of $3.9 Million ~ ~ Increased Full-Year 2018 Revenue Guidance for KEVEYIS from $16 to $19 Million to $18 to $20 Million ~ ~ MACRILEN™...

DUBLIN, Ireland and TREVOSE, Pa., May 03, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., April 26, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., March 26, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

DUBLIN, Ireland and TREVOSE, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

~ Data Suggest Levoketoconazole, the Isolated 2S,4R Enantiomer of Ketoconazole, Accounts for Essentially All of the Inhibition by Ketoconazole of Cortisol Biosynthesis in Humans ~  ~ Results...

~ KEVEYIS® (dichlorphenamide) Fourth Quarter and Full-Year 2017 Revenue of $3.0 Million and $7.0 Million, Respectively ~ ~ Full-Year 2018 KEVEYIS Revenue Guidance of $16 to $19 Million ~ ~ MACRILEN™...